<DOC>
	<DOCNO>NCT00189475</DOCNO>
	<brief_summary>Assesses efficacy treatment montelukast 10 mg PO QD x 5 day versus placebo treatment viral-induced upper respiratory infection healthy adult age 18-50 year .</brief_summary>
	<brief_title>Evaluate Potential Montelukast Prevent Nasal Symptomatology During Colds</brief_title>
	<detailed_description>This randomize double-blinded placebo control trial ass efficacy treatment montelukast 10 mg PO QD x 5 day versus placebo treatment viral-induced upper respiratory infection healthy adult age 18-50 year . All subject complete daily assessment cold symptom , nasal clearance rate secretion rate day study . Phlebotomy perform determination cytokine genotyping allergy skin test perform assessment atopy .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Respiratory Tract Infections</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>Adults 18 50 year age . Male female , pregnant lactating . Common cold symptom less 24 hour . At least 2 follow 9 symptom : cough , headache , hoarseness , muscle ache , nasal drainage , nasal congestion , scratch throat , sneeze malaise . Investigational medication past 30 day . Known hypersensitivity ingredient study medication . History asthma chronic disease . Females childbearing potential use medically acceptable form birth control . Patients nasal ulcer within past 1 month , nasal surgery within past 6 month , nasal trauma within past 2 month presence nasal polyp nasal deformity cause significant nasal obstruction . Females positive urinary HCG test . Patients positive rapid antigen test streptococcal infection . Common cold symptom 24 hour . Patients user illicit drug . Patients rifampin phenobarbital .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Cold</keyword>
	<keyword>Upper Respiratory Infection</keyword>
</DOC>